PBM
ACHV icon

Propel Bio Management’s Achieve Life Sciences ACHV Stock Holding History

Propel Bio Management’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3M Buy
4,034,018
+247,593
+7% +$1.18M 13.79% 2
2026
Q1 		$11.4M Hold
3,786,425
– – 7.17% 2
2025
Q4 		$18.8M Hold
3,786,425
– – 16.07% 2
2025
Q3 		$11.9M Sell
3,786,425
-2,366,666
-38% -$6.5M 11.94% 2
2025
Q2 		$13.9M Buy
6,153,091
+3,699,999
+151% +$10.5M 16.88% 2
2025
Q1 		$6.55M Hold
2,453,092
– – 7.61% 5
2024
Q4 		$8.63M Hold
2,453,092
– – 8.58% 4
2024
Q3 		$11.6M Hold
2,453,092
– – 6.74% 4
2024
Q2 		$11.5M Hold
2,453,092
– – 7.48% 5
2024
Q1 		$11.1M Buy
+2,453,092
New +$10.9M 6.49% 5

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Propel Bio Management's ACHV Position: Q2 2026 in Review

Propel Bio Management increased its Achieve Life Sciences (ACHV) stake by 6.5% in Q2 2026, buying an estimated $1.18M and bringing the position to 4,034,018 shares worth $26.3M. The position accounts for 13.79% of the portfolio, ranked #2.

Propel Bio Management first reported a position in ACHV in Q1 2024 and has held it in 10 quarters since. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Propel Bio Management held 4,034,018 shares of Achieve Life Sciences worth $26.3M as of Q2 2026.
  • Propel Bio Management bought 247,593 Achieve Life Sciences shares in Q2 2026, an estimated $1.18M.
  • Achieve Life Sciences made up 13.79% of Propel Bio Management's portfolio in Q2 2026, its #2 holding.
  • Propel Bio Management first reported a position in Achieve Life Sciences in Q1 2024 and has held it in 10 quarters since.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.